Table 6 Response rates with Pom/Dex... | American Society of Hematology

Table 6

Response rates with Pom/Dex according to number of prior regimens

	Median no. of prior regimens	Regimen	N	Schema	Doses, mg	≥ PR, %
Lacy⁵	2	Pom/Dex	60	28/28	2	63
Leleu⁸	4	Pom/Dex	43	21/28	4	42
Leleu⁸	4		41	28/28	4	39
Lacy⁶*	4	Pom/Dex	34	28/28	2	32
Richardson⁷	5	Pom +/−	120	21/28	4	25
Phase 2		Dex
Richardson⁷	6	Pom +/−	38	21/28	4	25
Phase 1		Dex			MTD
Current study†	6	Pom/Dex	35	28/28	2	26
Current study†	6		35		4	28

	Median no. of prior regimens	Regimen	N	Schema	Doses, mg	≥ PR, %
Lacy⁵	2	Pom/Dex	60	28/28	2	63
Leleu⁸	4	Pom/Dex	43	21/28	4	42
Leleu⁸	4		41	28/28	4	39
Lacy⁶*	4	Pom/Dex	34	28/28	2	32
Richardson⁷	5	Pom +/−	120	21/28	4	25
Phase 2		Dex
Richardson⁷	6	Pom +/−	38	21/28	4	25
Phase 1		Dex			MTD
Current study†	6	Pom/Dex	35	28/28	2	26
Current study†	6		35		4	28

Pom/Dex indicates pomalidomide, 2 mg daily, with weekly dexamethasone; PR, partial response; and MTD, maximal tolerated dose.

Lenalidomide refractory.

Lenalidomide and bortezomib refractory.